HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spriet, I. Articles by Willems, L. Search for Related Content PubMed PubMed Citation Articles by Spriet, I. Articles by Willems, L.

ISABEL SPRIET, PHARM.D., is a Ph.D. degree student, Department of Pharmacy; and WOUTER MEERSSEMAN, M.D., is Chest Physician, Medical Intensive Care Unit, University Hospital of Leuven (UHL), Leuven, Belgium. ELKE DE TROY, PHARM.D., is Clinical Pharmacist, Department of Pharmacy, Virga Jesse Hospital, Hasselt, Belgium. ALEXANDER WILMER, PH.D., M.D., is Associate Profesor of Medicine, Medical Intensive Care Unit, UHL. MINNE CASTEELS, M.D., PH.D., is Professor of Pharmacology, Department of Pharmacology, University of Leuven, Leuven. LUDO WILLEMS, PH.D., PHARM.D., is Head of Clinical Pharmacy, Department of Pharmacy, UHL.

Address correspondence to Dr. Spriet at the Department of Pharmacy, University Hospital of Leuven, Herestraat 49, 3000 Leuven, Belgium (isabel.spriet{at}uz.kuleuven.ac.be).

Purpose. Two case reports of rapid decreases in valproic acid levels after initiation of meropenem in patients who developed new-onset seizure activity during treatment with cefepime are presented. Summary. A 60-year-old Caucasian woman with myelodysplasia was transferred to the medical intensive care unit (MICU) on day 11 of her hospitalization. Cefepime was given as empiric therapy for febrile neutropenia. Pulmonary invasive aspergillosis was diagnosed. On day 16 of hospitalization, epileptic activity was confirmed. Valproic acid was initiated. Cefepime was discontinued and meropenem was initiated for treatment of cefepime-resistant pneumonia. Serum valproic acid levels decreased to subtherapeutic levels within 24 hours. Meropenem was discontinued and ceftazidime was started on day 22; serum valproic acid levels gradually increased but never reached therapeutic levels again. The patient died of intractable invasive aspergillosis on day 33. A 54-year-old Caucasian man with myelodysplasia was admitted to the MICU for nonconvulsive status epilepticus. Ten days before admission, cefepime had been started empirically for the treatment of neutropenic fever. One day before MICU admission, valproic acid was initiated as treatment for status epilepticus. The next day, serum valproic acid levels were therapeutic; cefepime was switched to mero penem. Serum valproic acid levels decreased within 24 hours and phenytoin was added. On day 4, the patient’s serum valproic acid levels decreased further and meropenem was discontinued. Although the valproic acid dosage was increased, valproic acid levels did not return to the therapeutic range. The patient died on day 11. Conclusion. Following cefepime therapy, a clinically important interaction between meropenem and valproic acid occurred in two critically ill patients with new-onset status epilepticus. Index terms: Antibiotics; Anticonvulsants; Blood levels; Cefepime; Cephalosporins; Drug interactions; Meropenem; Status epilepticus; Toxicity; Valproic acid

 

This article has been cited by other articles:

				I. Spriet, J. Goyens, W. Meersseman, A. Wilmer, L. Willems, and W. V. Paesschen Interaction Between Valproate and Meropenem: A Retrospective Study Ann. Pharmacother., July 1, 2007; 41(7): 1130 - 1136. [Abstract] [Full Text] [PDF]